Merck & Co
As on 18 Apr, 2026 | 01:29 IST
| Open | 115.79 |
| Previous Close | 115.46 |
| Beta | 0.45 |
| High | 119.14 |
| Low | 115.79 |
| TTM EPS See historical trend | 8.97(+17.41% YoY) |
| 52 Week High | 125.14 |
| 52 Week Low | 73.35 |
| TTM PE See historical trend | 13.27(Low PE) |
| Mkt. Cap ($ Billion) | 301.56 |
| Dividend Yield | 3.12 |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days |
|---|
Returns
| 1 Week | -1.94% | |
| 1 Month | 2.76% | |
| 3 Months | 9.35% | |
| YTD | 13.17% | |
| 1 Year | 52.75% | |
| 3 Years | 3.53% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | 926.70 | 2.51 | 881.48 | 38.30 | 24.21 | 0.58 | 1,133.95/623.99 | -0.39 | Neutral |
| J&J | 234.18 | -0.15 | 564.23 | 21.68 | 10.80 | 2.50 | 251.71/146.13 | -1.67 | Bearish |
| AbbVie | 208.38 | -0.29 | 368.20 | 20.84 | 10.00 | 2.91 | 244.80/168.66 | -5.19 | Very Bearish |
| Merck | 119.07 | 3.13 | 301.56 | 13.27 | 8.97 | 3.12 | 125.14/73.35 | 2.76 | Bullish |
| Amgen | 355.30 | 1.69 | 190.99 | 16.26 | 21.85 | 2.95 | 391.23/261.50 | -1.62 | Bullish |
Market news
- Wall St ends mixed, notches weekly gains as investors parse Middle East negotiationsApril 11, 2026 8:53 AM
- Wall Street skids as Middle East turmoil fans inflation fearMarch 21, 2026 9:02 AM
- Wall Street closes lower, posts weekly loss as war on Iran fuels inflation worriesMarch 14, 2026 8:59 AM
- US stocks close down as oil spikes 12%, job market weakensMarch 7, 2026 9:27 AM
About the company
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.